{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:57:44Z","timestamp":1790866664642,"version":"4.1.0"},"reference-count":42,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Ischemia\u2013reperfusion injury (IRI) is a clinically important consequence of blood-flow restoration after ischemia and contributes to tissue damage across multiple organ systems. This critical review evaluates the preclinical evidence for BPC 157 in rodent IRI and related reperfusion-associated vascular injury models, with particular attention to oxidative stress, endothelial and nitric oxide (NO)-related responses, inflammation, apoptosis, angiogenic signaling, and tissue injury. Searches were performed up to 24 June 2026 across PubMed\/MEDLINE, Web of Science Core Collection, Scopus, PMC, publisher\/DOI metadata, ClinicalTrials.gov, FDA materials, and WADA materials. Peer-reviewed rodent studies involving conventional organ-specific IRI or reperfusion-associated systemic injury were evaluated as the core IRI\/reperfusion evidence according to the experimental model, BPC 157 dose, route and timing, measured outcomes, and methodological limitations, while selected major-vessel occlusion models were considered separately as related in vivo vascular evidence. Endothelial, vascular-ring, human ex vivo, and regulatory\/clinical sources were used as contextual evidence rather than as evidence of IRI efficacy. Meta-analysis was not performed because of substantial heterogeneity in organ systems, injury paradigms, doses, routes, treatment timing, and outcome measures. Across the available rodent literature, BPC 157 administration has been associated with attenuation of oxidative injury, modulation of NO-related vascular responses, reductions in inflammatory and apoptotic markers, and changes in VEGF\/VEGFR2\u2013Akt\u2013eNOS-related signaling. Organ-specific findings include biochemical, molecular, and histological protection in lower-extremity skeletal-muscle IRI; attenuation of distant-organ injury following limb IRI; neuronal and functional effects in hippocampal IRI; vascular and tissue-protective responses in intestinal\/colonic IRI; and hemodynamic and histological effects in hepatic Pringle-maneuver IRI. However, the evidence base remains heterogeneous and frequently relies on short observation periods, single-dose paradigms, and incompletely characterized risk-of-bias domains. Reperfusion-like systemic and major-vessel occlusion models provide additional mechanistic context but should not be considered equivalent to conventional organ-specific IRI. Current evidence therefore supports BPC 157 as a hypothesis-generating investigational candidate for further preclinical IRI research rather than as an established therapy. Independent blinded replication, dose\u2013response and therapeutic-window studies, pharmacokinetic\/pharmacodynamic characterization, rigorous toxicology, and ultimately controlled human studies would be required before clinical translation could be considered.<\/jats:p>","DOI":"10.3390\/ijms27188344","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:23:56Z","timestamp":1790864636000},"page":"8344","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BPC 157 in Rodent Ischemia\u2013Reperfusion Injury: A Critical Review of Preclinical Evidence"],"prefix":"10.3390","volume":"27","author":[{"given":"H\u00fcseyin","family":"Demirta\u015f","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Surgery, Faculty of Medicine, Gazi University, 06510 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/B978-0-12-394309-5.00006-7","article-title":"Cell biology of ischemia\/reperfusion injury","volume":"298","author":"Kalogeris","year":"2012","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/nm.2507","article-title":"Ischemia and reperfusion-from mechanism to translation","volume":"17","author":"Eltzschig","year":"2011","journal-title":"Nat. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6","article-title":"Pathophysiology of ischaemia-reperfusion injury","volume":"190","author":"Carden","year":"2000","journal-title":"J. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1172\/JCI62874","article-title":"Myocardial ischemia-reperfusion injury: A neglected therapeutic target","volume":"123","author":"Hausenloy","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.redox.2015.08.020","article-title":"Reperfusion injury and reactive oxygen species: The evolution of a concept","volume":"6","author":"Granger","year":"2015","journal-title":"Redox Biol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Demirtas, H., Ozer, A., Yildirim, A.K., Dursun, A.D., Sezen, S.C., and Arslan, M. (2025). Protective effects of BPC 157 on liver, kidney, and lung distant organ damage in rats with experimental lower-extremity ischemia-reperfusion injury. Medicina, 61.","DOI":"10.3390\/medicina61020291"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00109-016-1488-y","article-title":"Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation","volume":"95","author":"Hsieh","year":"2017","journal-title":"J. Mol. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"17078","DOI":"10.1038\/s41598-020-74022-y","article-title":"Modulatory effects of BPC 157 on vasomotor tone and the activation of the Src-caveolin-1-endothelial nitric oxide synthase pathway","volume":"10","author":"Hsieh","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Seiwerth, S., Milavic, M., Vukojevic, J., Gojkovic, S., Krezic, I., Vuletic, L.B., Pavlov, K.H., Petrovic, A., Sikiric, S., and Vranes, H. (2021). Stable gastric pentadecapeptide BPC 157 and wound healing. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.627533"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Jozwiak, M., Bauer, M., Kamysz, W., and Kleczkowska, P. (2025). Multifunctionality and possible medical application of the BPC 157 pep-tide-literature and patent review. Pharmaceuticals, 18.","DOI":"10.3390\/ph18020185"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mateescu, D.M., Gavrilescu, D.M., Constantinescu, F.E., Oancea, C., Ilie, A.C., Folescu, R., Popa, M.-D., Iurciuc, S., Muresan, C.-O., and Enache, A. (2026). BPC-157 as an investigational peptide therapeutic: Biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics, 18.","DOI":"10.3390\/pharmaceutics18050625"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Yuan, C., Demers, A., Silva-Ortiz, V., Hasoon, J.J., Lee, W., Dave, K., Amirdelfan, K., Burke, H.W., Christo, P.J., and Robinson, C.L. (2026). From regeneration to analgesia: The role of BPC-157 in tissue repair and pain management. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27062876"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"24375","DOI":"10.1038\/s41598-026-55449-1","article-title":"Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury","volume":"16","author":"Yildirim","year":"2026","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e01726","DOI":"10.1002\/brb3.1726","article-title":"The effect of pentadecapeptide BPC 157 on hippocampal ischemia\/reperfusion injuries in rats","volume":"10","author":"Vukojevic","year":"2020","journal-title":"Brain Behav."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8465","DOI":"10.3748\/wjg.v23.i48.8465","article-title":"Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights","volume":"23","author":"Duzel","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4254\/wjh.v12.i5.184","article-title":"Pentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion","volume":"12","author":"Kolovrat","year":"2020","journal-title":"World J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Tepes, M., Krezic, I., Vranes, H., Smoday, I.M., Kalogjera, L., Zizek, H., Vukovic, V., Oroz, K., Kovac, K.K., and Madzar, Z. (2023). Stable gastric pentadecapeptide BPC 157 therapy: Effect on reperfusion following maintained intra-abdominal hypertension (grade III and IV) in rats. Pharmaceuticals, 16.","DOI":"10.3390\/ph16111554"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.vph.2018.02.010","article-title":"Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157","volume":"106","author":"Vukojevic","year":"2018","journal-title":"Vasc. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.3748\/wjg.v24.i47.5366","article-title":"Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine","volume":"24","author":"Amic","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Yildirim, A.K., Dastan, A.O., Demeli Ertus, M., Ensarioglu, M., Karabacak, K., and Pehlivanoglu, B. (2026). Endothelium-dependent nitric oxide-mediated vasorelaxant effects of BPC 157 in human internal mammary artery. J. Clin. Med., 15.","DOI":"10.3390\/jcm15093488"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Hooijmans, C.R., Rovers, M.M., de Vries, R.B.M., Leenaars, M., Ritskes-Hoitinga, M., and Langendam, M.W. (2014). SYRCLE\u2019s risk of bias tool for animal studies. BMC Med. Res. Methodol., 14.","DOI":"10.1186\/1471-2288-14-43"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6614009","DOI":"10.1155\/2021\/6614009","article-title":"Role of oxidative stress in reperfusion following myocardial ischemia and its treatments","volume":"2021","author":"Xiang","year":"2021","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"H1553","DOI":"10.1152\/ajpheart.00158.2018","article-title":"Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury","volume":"315","author":"Toldo","year":"2018","journal-title":"Am. J. Physiol.-Heart Circ. Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41392-023-01688-x","article-title":"Ischemia-reperfusion injury: Molecular mechanisms and therapeutic targets","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s12640-009-9110-5","article-title":"Endoplasmic reticulum stress plays critical role in brain damage after cerebral ische-mia\/reperfusion in rats","volume":"17","author":"Nakka","year":"2010","journal-title":"Neurotox. Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wang, L., Liu, Y., Zhang, X., Ye, Y., Xiong, X., Zhang, S., Gu, L., Jian, Z., and Wang, H. (2022). Endoplasmic reticulum stress and the unfolded protein response in cerebral ischemia\/reperfusion injury. Front. Cell. Neurosci., 16.","DOI":"10.3389\/fncel.2022.864426"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Sikiric, P., Seiwerth, S., Skrtic, A., Staresinic, M., Strbe, S., Vuksic, A., Sikiric, S., Bekic, D., Soldo, D., and Grizelj, B. (2025). Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System. Pharmaceuticals, 18.","DOI":"10.3390\/ph18060928"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s12178-025-09990-7","article-title":"Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing","volume":"18","author":"McGuire","year":"2025","journal-title":"Curr. Rev. Musculoskelet. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s00595-007-3706-2","article-title":"Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat","volume":"38","author":"Novinscak","year":"2008","journal-title":"Surg. Today"},{"key":"ref_30","first-page":"BR81","article-title":"Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application","volume":"16","author":"Pevec","year":"2010","journal-title":"Med. Sci. Monit."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Matek, D., Matek, I., Japjec, M., Matek, M., Prenc, J., Staresinic, B., Staresinic, E., Prtoric, A., Sikiric, S., and Oreskovic, L.B. (2026). Tendon, ligament, and muscle injury, osteotendinous, myotendinous, and muscle-to-bone junction therapy perspectives with growth factors and stable gastric pentadecapeptide BPC 157\u2014A review. Pharmaceuticals, 19.","DOI":"10.3390\/ph19020309"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Barisic, I., Balenovic, D., Udovicic, M., Bardak, D., Strinic, D., Vlainic, J., Vranes, H., Smoday, I.M., Krezic, I., and Milavic, M. (2022). Stable gastric pentadecapeptide BPC 157 may counteract myocardial infarction induced by isoprenaline in rats. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020265"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Sikiric, P., Barisic, I., Udovicic, M., Bencic, M.L., Balenovic, D., Strinic, D., Posilovic, G.Z., Uzun, S., Vranes, H., and Krezic, I. (2026). Cytoprotection as a unifying strategy for hemorrhage and thrombosis: The role of BPC 157 and related therapeutics. Pharmaceuticals, 19.","DOI":"10.3390\/ph19030463"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Smoday, I.M., Vukovic, V., Oroz, K., Vranes, H., Kalogjera, L., Gamulin, O., Vlainic, J., Milavic, M., Sikiric, S., and Gabaj, N.N. (2026). Unilateral adrenalectomy, and the stable pentadecapeptide BPC 157 as therapy in rats-a cytoprotection approach. Pharmaceuticals, 19.","DOI":"10.3390\/ph19060873"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Madzarac, G., Becejac, T., Penovic, T., Drazenovic, D., Kralj, L., Dolic, M.P., Sikiric, S., Oreskovic, L.B., Oreskovic, I., and Strbe, S. (2026). Tracheocutaneous fistula resolved by pentadecapeptide BPC 157 therapy through the NO-system-triple NO-agent approach in rats. Pharmaceuticals, 19.","DOI":"10.3390\/ph19010145"},{"key":"ref_36","unstructured":"U.S. Food and Drug Administration (2026, September 10). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, Available online: https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks."},{"key":"ref_37","unstructured":"U.S. Food and Drug Administration (2026, September 10). July 23\u201324, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar, Available online: https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026."},{"key":"ref_38","unstructured":"World Anti-Doping Agency (2026, September 10). The 2026 Prohibited List: World Anti-Doping Code. Valid 1 January 2026. Available online: https:\/\/www.wada-ama.org\/sites\/default\/files\/2025-09\/2026list_en_final_clean_september_2025.pdf."},{"key":"ref_39","unstructured":"ClinicalTrials.gov (2026, September 10). NCT02637284: PCO-02\u2014Safety and Pharmacokinetics Trial, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02637284."},{"key":"ref_40","unstructured":"ClinicalTrials.gov (2026, September 10). NCT07437547: BPC 157 for Acute Hamstring Muscle Strain Repair (BPC-HAMSTR), Available online: https:\/\/clinicaltrials.gov\/study\/NCT07437547."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Lee, H.-M., Choi, J.W., and Choi, M.S. (2022). Role of Nitric Oxide and Protein S-Nitrosylation in Ischemia-Reperfusion Injury. Antioxidants, 11.","DOI":"10.3390\/antiox11010057"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"du Sert, N.P., Hurst, V., Ahluwalia, A., Alam, S., Avey, M.T., Baker, M., Browne, W.J., Clark, A., Cuthill, I.C., and Dirnagl, U. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol., 18.","DOI":"10.1371\/journal.pbio.3000410"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8344\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:25:13Z","timestamp":1790864713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":42,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188344"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188344","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]}}}